Squarepoint
MLTX icon

Squarepoint’s MoonLake Immunotherapeutics MLTX Stock Holding History

Squarepoint’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,900
Closed -$92.5K – 4647
2025
Q3 		$92.5K Buy
+12,900
New +$672K ﹤0.01% 4126
2025
Q1 		– Sell
-13,000
Closed -$704K – 5105
2024
Q4 		$704K Buy
+13,000
New +$664K ﹤0.01% 3406
2024
Q3 		– Sell
-12,500
Closed -$550K – 4474
2024
Q2 		$550K Buy
+12,500
New +$529K ﹤0.01% 3006

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's MLTX Position: Q1 2026 in Review

Squarepoint reduced its MoonLake Immunotherapeutics (MLTX) stake by 9.4% in Q1 2026, selling an estimated $189K and leaving 110,217 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Squarepoint first reported a position in MLTX in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.11M in Q2 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Squarepoint held 110,217 shares of MoonLake Immunotherapeutics worth $2.05M as of Q1 2026.
  • Squarepoint sold 11,423 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $189K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2161 holding.
  • Squarepoint first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 10 quarters since.
  • Squarepoint's MoonLake Immunotherapeutics position peaked at $2.11M in Q2 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.